Sorry, you need to enable JavaScript to visit this website.

Nasal Spray Treatment for Treatment-Resistant Depression (TRD) | SPRAVATO® (esketamine)
For adults:
If you struggle with
treatment-resistant depression,
there’s a different choice to turn to.
 
Nasal Spray

Taken along with an oral antidepressant: SPRAVATO® is the first nasal spray medication specifically for adults with treatment-resistant depression.

If you’ve tried two or more antidepressants* and are still struggling with depressive symptoms, talk to your doctor to see if you may have treatment-resistant depression.

*Of adequate dose and duration in your current episode.

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe and effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

Ask your doctor if SPRAVATO® may be right for you.

 

In a clinical study of adults with 
treatment-resistant depression:

Those who took SPRAVATO® and an oral antidepressant experienced greater reductions of depressive symptoms at four weeks compared to those who received a placebo plus an oral antidepressant.

Based on an overall score on a standardized rating scale.

Most common side effects of SPRAVATO®:

Feeling disconnected from yourself, your thoughts, feelings and things around you (dissociation); dizziness; nausea; feeling sleepy (sedation); spinning sensation; decreased feeling of sensitivity (numbness); feeling anxious; lack of energy; increased blood pressure; vomiting; feeling drunk; and feeling very happy or excited.

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®. Learn more about possible side effects here.

SPRAVATO® is only available at certified SPRAVATO® treatment centers under the supervision of a healthcare provider.

As part of the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program, a healthcare provider will discuss the risks of sedation, dissociation, and abuse and misuse with you before starting SPRAVATO®. You and a healthcare provider must complete a Patient Enrollment Form for you to receive SPRAVATO® in a certified treatment center.

IFU TRD Thumbnail
Discussion guide

Discussion Guide

Download our helpful guide on how to discuss starting SPRAVATO® with your healthcare provider and insurance company.

Patient Videos

Patients and caregivers who are living with treatment-resistant depression share their experiences with SPRAVATO®.

SPRAVATO® works differently than other medications to target treatment-resistant depression.

SPRAVATO® is taken with an oral antidepressant.

Frequently Asked Questions

Healthcare providers may define the term “treatment-resistant depression” differently. In the SPRAVATO® clinical trials, treatment-resistant depression was diagnosed in adults who were struggling with major depressive disorder and had not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.

SPRAVATO® (esketamine) CIII nasal spray is the first prescription nasal spray, taken with an oral antidepressant, for:

  • Adults with treatment-resistant depression
  • Depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe and effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

Talk to your healthcare provider to see if SPRAVATO® may be right for you. SPRAVATO® is a prescription medicine given by nasal spray and taken with an oral antidepressant to improve the symptoms of depression in adults who have treatment-resistant depression. Be sure to tell your healthcare provider if you have a history of abusing prescription or street drugs, or a problem with alcohol. You should also tell your healthcare provider if you are pregnant, planning to become pregnant, are breastfeeding or planning to breastfeed. Do not take SPRAVATO® if you are pregnant or breastfeeding. Do not take SPRAVATO® if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or if you are allergic to esketamine, ketamine or any of the ingredients in SPRAVATO®. Talk to your healthcare provider about all of your health conditions and medications when discussing treatment with SPRAVATO®.